Skip to main content

Table 1 Patient baseline and treatment characteristics; patients still under therapy are not included in follow-up/outcome analysis

From: Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial

characteristic   range
median age (years), n = 18 57 44 - 69
median follow-up (months), n = 14 excluding pts under treatment 17.4 6.5 - 30
deceased (pts) 1  
male (pts) 16  
female (pts) 5  
Site (n = 18)   
palate (pts) 2  
oropharynx 7  
hypopharynx 6  
larynx 3  
Stage (n = 18)   
T2 3  
T3 8  
T4 7  
N0 2  
N2b 4  
N2c 11  
N3 1  
therapy (n = 14)   
median dose (cervical lymph nodes)/Gy 50 49 - 51
median dose (primary and involved nodes)/Gy 20 19 - 24
median total dose/Gy 70 69 - 74